ALC Alcon Inc.

Alcon Launches PRECISION1 for Astigmatism Contact Lenses in the U.S.

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announced the U.S. launch of PRECISION1® for Astigmatism, a daily disposable, silicone hydrogel (SiHy) contact lens designed for astigmatic patients.

This press release features multimedia. View the full release here:

PRECISION1® for Astigmatism Logo (Graphic: Business Wire)

PRECISION1® for Astigmatism Logo (Graphic: Business Wire)

“PRECISION1, with its cutting-edge SMARTSURFACE® technology, has become the fastest-growing daily disposable contact lens brand in the U.S.,” said Sergio Duplan, President, Alcon North America. “We are thrilled to build on this momentum by introducing PRECISION1 for Astigmatism, Alcon’s first daily disposable, SiHy toric lens at a mainstream price. This innovation offers Eye Care Professionals a lens for more of their astigmatic patients to start in and stay in.”

PRECISION1 for Astigmatism, born from the Water Gradient Technology of DAILIES TOTAL1®, features the proven PRECISION BALANCE 8|4® lens design for a stable lens-wearing experience.1-3 Clinical studies show the toric lens settles in less than 60 seconds and 3º of ideal orientation for a 99% first fit success rate.2* Additionally, a single 6 o’clock scribe mark makes fitting exceptionally easy.2

Astigmatism is a common vision problem caused by an irregularly shaped cornea. This can cause images to blur or stretch out. Alcon estimates that toric lenses, which correct for astigmatism, represent 23% of the $9 billion global contact lens market.4 As a result, there is a significant opportunity to attract new contact lens wearers and reduce lens dropouts. For example, studies show that 41% of patients are astigmatic,5 but only 10% wear toric contact lenses.6 Further, about 65% of contact lens dropouts have astigmatism.6

Born from Water Gradient Technology, PRECISION1 lenses feature SMARTSURFACE Technology, a permanent micro-thin, high-performance layer of moisture that steps up from 51% water at the core to greater than 80% water at the outer surface.7 These lenses support a stable tear film to deliver lasting performance.7

“Many of my patients want long-lasting comfort from their daily disposable contact lens, and that’s led me to wholeheartedly prescribe PRECISION1,” said Aaron Luekenga, OD, Heritage Valley Eye Care, California.** “Now with PRECISION1 for Astigmatism, I can offer my astigmatic patients a stable, next-generation lens-wearing experience.”

PRECISION1 and PRECISION1 for Astigmatism are available in optical retailers/practices and online throughout the United States. Eye Care Professionals, with or without fit sets, will have access to order trial and revenue lenses directly from Alcon or an Alcon-authorized distributor.

In addition, PRECISION1 and PRECISION1 for Astigmatism will begin to roll out concurrently worldwide beginning in February 2021.

For more information, visit .

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. In particular, our expectations could be affected by uncertainties regarding the success of our separation and spin-off from Novartis. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.

Forward-looking statements in this press release speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at .

References

^Trademarks are the property of their respective owners.

*Based on lens movement, centration and rotation at initial fitting.

**Dr. Luekenga is a paid consultant for Alcon.

  1. Alcon data on File, 2019.
  2. Alcon data on File, 2020 (n=78 eyes).
  3. In a randomized, subject-masked, multi-site study with over 150 patients; significance demonstrated at the 0.05 level; Alcon data on file, 2005.
  4. Alcon Estimates and independent market research.
  5. Luensmann, D., Contact Lens and Anterior Eye (2018).
  6. Multi-Sponsor Surveys 2014 Gallup target market report.
  7. Alcon data on file, 2019.
  8. Based on share growth, private practice sales, Q1-Q3 2020; ABB Analyze powered by GLIMPSE.
  9. Private practice sales, on average, Q1-Q3 2020; ABB Analyze powered by GLIMPSE.
  10. Miller J, Giedd B, Subbaraman L. Clinical comparison of verofilcon A and etafilcon A daily disposable contact lenses. Poster presented at virtual American Academy of Optometry 2020 annual meeting; October 7 - 22, 2020.

Connect with us on



EN
20/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Alcon Inc.

 PRESS RELEASE

Alcon Agrees to Acquire LENSAR, Inc.

GENEVA, Switzerland & ORLANDO, Fla.--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire LENSAR. The acquisition includes ALLY Robotic Cataract Laser Treatment System™, LENSAR’s proprietary Streamline® software technology and LENSAR legacy laser system, building Alcon’s femtosecond...

 PRESS RELEASE

Alcon to Host 2025 Capital Markets Day

GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care, will host its 2025 Capital Markets Day on March 27, 2025, beginning at 8:00 a.m. CT. A live webcast of the event will be available at the following link: . Those wishing to participate should register and log on approximately 10 minutes before the start of the webcast. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care product...

 PRESS RELEASE

Alcon Canada renforce son engagement envers les patients atteints d’as...

TORONTO--(BUSINESS WIRE)-- Alcon (SIX/NYSE : ALC), le chef de file mondial en matière de soins oculaires qui se consacre à aider les gens à voir avec clarté, a annoncé aujourd’hui l’ajout de paramètres élargis à la gamme de lentilles TOTAL30MD pour l’astigmatisme, les premières et les seules lentilles cornéennes toriques à remplacement mensuel avec gradient d’eau1-3 qui procurent la même expérience de port exceptionnellement confortable5, maintenant offertes avec une puissance cylindrique de -2,75 D. Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : L...

 PRESS RELEASE

Alcon Canada Strengthens its Commitment to Astigmatic Patients with TO...

TORONTO--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the availability of expanded parameters for TOTAL30® for Astigmatism, the first and only monthly replacement Water Gradient toric contact lens,1-3 delivering the same exceptionally comfortable wearing experience,5 now in a –2.75D cylinder offering. This press release features multimedia. View the full release here: TOTAL30 for Astigmatism, the first and only monthly replacement Water Gradient toric contact lens, is now available in expanded parameters. (...

 PRESS RELEASE

Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earning...

GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2024. For the fourth quarter of 2024, sales were $2.5 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.57 and core diluted earnings per share2 of $0.72 in the fourth quarter of 2024. "In 2024, our unwavering focus on innovation and operational excellence delivered another set of strong results," said Dav...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch